Product Images Cinryze
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 31 images provide visual information about the product associated with Cinryze NDC 42227-083 by Takeda Pharmaceuticals America, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - cinryze 01
Figure 2 - cinryze 02
Figure 3 - cinryze 03
Figure 4 - cinryze 04
Figure 5 - cinryze 05
Figure 6 - cinryze 06
Figure 7 - cinryze 07
Figure 8 - cinryze 08
Figure 9 - cinryze 09
Figure 10 - cinryze 10
Figure 11 - cinryze 11
Figure 12 - cinryze 12
Figure 13 - cinryze 13
Figure 14 - cinryze 14
Figure 15 - cinryze 15
Figure 16 - cinryze 16
Figure 17 - cinryze 17
Figure 18 - cinryze 18
Figure 19 - cinryze 19
Figure 20 - cinryze 20
Figure 21 - cinryze 21
Figure 22 - cinryze 22
Figure 23 - cinryze 23
Figure 24 - cinryze 24
Figure 25 - cinryze 25
Figure 26 - cinryze 26
Figure 27 - cinryze 27
PRINCIPAL DISPLAY PANEL - 500 U Vial Label - cinryze 28
CINRYZE is a sterile water-based solution intended for intravenous injection, used for treating Hereditary Angioedema (HAE) attacks. The solution contains C1 esterase inhibitor which is human in origin. The medication needs to be reconstituted with sterile water and should be used within 3 hours of reconstitution. It is important to discard any unused contents. This is a single-dose medication and should only be used under prescription by a healthcare professional. The manufacturer of CINRYZE is YiroPhama Biologis LLC, located in Lexington, MA. The lot number is not available.*
PRINCIPAL DISPLAY PANEL - 500 U Vial Carton - cinryze 29
This is a description of CINRYZE®, a medication used for intravenous injection. It is a C1 esterase inhibitor derived from human plasma and comes in a single-dose vial containing 500 U of the medication, which should be stored at 2°C=25°C (36°F77°F). Reconstitution requires 5 mL of Sterile Water for Injection, USP. The medication does not contain any preservatives and must be used within 3 hours of reconstitution. Inactive ingredients are listed in the package insert. The description warns that plasma-derived products, such as this medication, may carry a risk of transmitting infectious agents. Users should refer to the package insert for all warnings and precautions. The medication is manufactured by ViroPharma Bioogics LLC in Levington, MA, and is a product of Austria. The US License No. for this medication is 1833.*
Principal Display Panel - 5 mL Vial Label - cinryze 30
This is a description of a single-dose container of sterile water used to reconstitute another product. The water should not be used if an antimicrobial agent or other substance has been added, and should not be injected intravascularly without making it isotonic by adding a suitable solute. The container should be discarded if any unused portion remains. It is only for prescription use and is nonpyrogenic.*
Principal Display Panel - Kit Carton - cinryze 31
This is a product description for CINRYZE, a C1 esterase inhibitor (human) used for intravenous injection. The product is manufactured in Austria and Germany, and contains a single 500 1U vial of CINRYZE and a 5 mL vial of sterile water for injection. The package insert should be consulted for full instructions and warnings.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.